Welcome to our dedicated page for Xometry SEC filings (Ticker: XMTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xometry鈥檚 Instant Quoting Engine may simplify custom part pricing, but its SEC paperwork is another story. Revenue from a two-sided marketplace, segment splits between U.S. and International operations, and fast-growing AI R&D lines make the annual report dense. If you have ever searched for 鈥淴ometry SEC filings explained simply鈥� or tried piecing together supplier metrics across multiple notes, you already know the challenge.
Stock Titan solves it. Our platform delivers AI-powered summaries the moment a document hits EDGAR, turning a 300-page 10-K into the highlights you actually need. Whether you鈥檙e scanning a 鈥淴ometry quarterly earnings report 10-Q filing鈥� for marketplace take-rate, reviewing 鈥淴ometry insider trading Form 4 transactions鈥� before an earnings call, or comparing cost of revenue trends, everything is organized and searchable. AG真人官方-time alerts flag 鈥淴ometry Form 4 insider transactions real-time鈥� and 鈥淴ometry 8-K material events explained鈥� within minutes, so you never miss an update.
- 鈥淴ometry annual report 10-K simplified鈥� 鈥� see segment revenue, AI investment, and risk factors without wading through accounting jargon.
- 鈥淴ometry executive stock transactions Form 4鈥� 鈥� monitor buying or selling activity alongside price-impact charts.
- 鈥淴ometry earnings report filing analysis鈥� 鈥� track margins, active buyer counts, and cash burn across quarters.
- 鈥淴ometry proxy statement executive compensation鈥� 鈥� understand incentive structures tied to marketplace growth.
From the first look at new guidance in an 8-K to deeper dives on cash flow in a 10-Q, Stock Titan keeps each disclosure actionable. Use our AI context engine for understanding Xometry SEC documents with AI鈥攕o you can focus on decisions, not document hunts.
Under Armour, Inc. (ticker: UAA/UA) has filed a Form 4 indicating that board member Mohamed El-Erian acquired 3,338.28 Class C common shares on 07/01/2025.
The shares were issued at $0.00 under the company鈥檚 Fiscal Year 2025 Non-Employee Director Compensation Plan, meaning the award represents deferred stock units in lieu of cash director fees rather than an open-market purchase.
After the grant, El-Erian鈥檚 direct holdings stand at 172,457.93 Class C shares and 11,650 Class A shares. No derivative positions were reported and no shares were sold.
This filing reflects routine board compensation and is not indicative of a strategic share-accumulation program. The transaction is immaterial relative to Under Armour鈥檚 total share count and should have negligible impact on valuation or governance dynamics.
GS Finance Corp. is offering $1.08 million of Autocallable Contingent Coupon Equity-Linked Notes due 2028, fully and unconditionally guaranteed by The Goldman Sachs Group, Inc. The notes are tied to the performance of Palantir Technologies Inc. (PLTR) Class A common shares and form part of Goldman鈥檚 Series F medium-term note program.
Key commercial terms
- Face amount: $1,000 per note (aggregate $1.08 million)
- Issue price: 100% (trade date 30-Jun-2025; settlement 03-Jul-2025)
- Quarterly contingent coupon: $69.625 (6.9625% per quarter, up to 27.85% p.a.) payable only if PLTR closes at or above 60% of the initial price ($136.32) on the relevant observation date.
- Automatic call: If PLTR closes at or above the initial price on any quarterly call observation date from Sep-2025 to Mar-2028, the notes are redeemed at par plus the due coupon.
- Downside protection: 40% buffer. If the final price on 30-Jun-2028 is 鈮�60% of the initial price, holders receive par plus any final coupon. If below 60%, repayment equals par plus (index return 脳 par), exposing investors to full downside beyond the buffer.
- Estimated value at pricing: ~$970 per $1,000, reflecting structuring fees and dealer margin; underwriting discount 2%.
- Secondary market: GS & Co. may, but is not obliged to, make a market; bid/ask reflects estimated value plus declining premium (initially $25).
- Credit: senior unsecured obligation of GS Finance Corp. with unconditional guarantee from The Goldman Sachs Group, Inc.; not FDIC insured.
Risk highlights
- Investors may receive no coupons if PLTR trades below the 60% trigger on observation dates.
- If PLTR falls >40% at maturity and the note hasn鈥檛 been called, principal loss is one-for-one with the stock鈥檚 decline.
- Limited upside: maximum redemption is par plus due coupon; investors do not participate in stock gains above par.
- Market value likely to be below issue price; liquidity limited; pricing sensitive to GS credit spreads, PLTR volatility and interest rates.
- Product complexity, dilution events, market disruption adjustments and discretionary determinations by GS & Co. add additional risks.
The prospectus supplement also details anti-dilution adjustments, default provisions, tax characterization (income-bearing prepaid derivative contract) and extensive hypothetical scenarios illustrating coupon and principal outcomes.
Form 4 overview: Director Laura Berner of Bolt Biotherapeutics (BOLT) reported a single equity-based transaction dated May 27 2025. She received a non-qualified stock option for 1,100 common shares at an exercise price of $6.40 per share. All figures give effect to the 1-for-20 reverse stock split that the company executed on June 6 2025.
Key terms of the grant:
- Vesting: Options vest on the earlier of May 27 2026 or the day immediately prior to the next annual meeting, subject to continued service.
- Change-in-control: The award vests in full upon a change-in-control event.
- Expiration: May 26 2035 (10-year life).
No shares were purchased or sold; the filing reflects compensation-related option issuance. Post-grant, Berner beneficially owns 1,100 derivative securities and no disclosed non-derivative common shares.
Corporate context: The recent reverse split consolidated each 20 common shares into one, reducing the share count and proportionally increasing exercise prices. Prior to the split, the grant was for 22,000 shares at $0.32 per share. The filing provides no additional financial or operational data.
Form 4 insider update for Kartoon Studios (TOON)
Director Anthony D. Thomopoulos reported the acquisition of 6,805 common shares on 06/26/2025. The transaction was recorded under code 鈥淎,鈥� indicating an award or similar grant, at a stated price of $0.00. After this grant, Thomopoulos鈥� direct beneficial ownership rises to 105,711 shares.
No derivative securities were exercised or disposed of, and no cash consideration was involved. The filing reiterates the company鈥檚 10-for-1 reverse stock split completed on 02/06/2023, which consolidated historical share counts.
- Insider: Anthony D. Thomopoulos (Director)
- Shares acquired: 6,805
- Total shares owned post-transaction: 105,711
- Transaction type: Award/Grant (Code A)
The size of the grant is modest relative to total shares outstanding and does not, by itself, signal a material change in corporate outlook, but it does modestly increase insider alignment.
Xometry, Inc. (Nasdaq: XMTR) filed an 8-K to disclose the voting results of its 2025 Annual Meeting of Stockholders held on 18 June 2025. The meeting covered three routine governance matters鈥攁ll of which received strong shareholder support.
- Director election (Class I): Co-founder & CEO Randolph Altschuler was re-elected to the Board until the 2028 AGM. Votes FOR: 64,396,222; WITHHELD: 5,822,012; BROKER NON-VOTES: 4,373,305, implying c. 92 % support of votes cast.
- Say-on-pay (advisory): Compensation of named executive officers was approved by 68,132,494 votes FOR versus 2,035,694 AGAINST and 50,046 ABSTAIN鈥攔oughly 96 % shareholder approval. The company will continue holding say-on-pay votes annually, consistent with prior practice.
- Auditor ratification: Deloitte & Touche LLP was reappointed as independent auditor for FY-2025 with near-unanimous support (FOR: 74,561,074; AGAINST: 4,030; ABSTAIN: 26,435).
No other matters were brought before the meeting, and no financial results, strategic transactions, or operational updates were disclosed in this filing. The 8-K therefore conveys standard corporate-governance information; while positive in demonstrating strong shareholder alignment, it is unlikely to be a material catalyst for XMTR鈥檚 share price.
Form 4 filing for Xometry, Inc. (XMTR) dated 06/18/2025 details a small, pre-planned sale of Class A common stock by Chief Operating Officer Peter Goguen.
- Shares sold: 986 shares across two transactions on 06/17/2025.
- Prices: Weighted-average prices of $30.5116 (888 shares) and $30.925 (98 shares).
- Purpose: Sales executed automatically under a Rule 10b5-1 plan and used to cover tax-withholding obligations arising from restricted-stock-unit vesting.
- Post-sale ownership: 175,457 Class A shares remain under direct ownership, implying only a ~0.6 % reduction in the executive鈥檚 stake.
No derivative transactions, new grants, or material changes in ownership structure were reported. Given the modest size, 10b5-1 automation, and tax-coverage motivation, the filing appears routine and is unlikely to materially affect the investment thesis for XMTR.
FAQ
What is the current stock price of Xometry (XMTR)?
What is the market cap of Xometry (XMTR)?
What is Xometry, Inc.'s core business?
How does the Xometry Instant Quoting Engine work?
Which manufacturing processes does Xometry support?
How does Xometry ensure supply chain resiliency?
What differentiates Xometry from other manufacturing platforms?
Who are Xometry's typical customers?
What role does technology play in Xometry's operations?
How does Xometry support international operations?
